Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
Eggermont, Alexander MM, Prof, Suciu, Stefan, PhD, Santinami, Mario, MD, Testori, Alessandro, MD, Kruit, Wim HJ, MD, Marsden, Jeremy, MD, Punt, Cornelis JA, Prof, Salès, François, MD, Gore, Martin, Prof, MacKie, Rona, Prof, Kusic, Zvonko, Prof, Dummer, Reinhard, Prof, Hauschild, Axel, Prof, Musat, Elena, MD, Spatz, Alain, MD, Keilholz, Ulrich, Prof
Published in The Lancet (British edition) (12.07.2008)
Published in The Lancet (British edition) (12.07.2008)
Get full text
Journal Article
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Corrie, Pippa G, Dr, Marshall, Andrea, PhD, Dunn, Janet A, Prof, Middleton, Mark R, Prof, Nathan, Paul D, PhD, Gore, Martin, Prof, Davidson, Neville, Prof, Nicholson, Steve, PhD, Kelly, Charles G, FRCR, Marples, Maria, PhD, Danson, Sarah J, PhD, Marshall, Ernest, MD, Houston, Stephen J, MD, Board, Ruth E, PhD, Waterston, Ashita M, PhD, Nobes, Jenny P, FRCR, Harries, Mark, PhD, Kumar, Satish, MD, Young, Gemma, MPhil, Lorigan, Paul, MD
Published in The lancet oncology (01.05.2014)
Published in The lancet oncology (01.05.2014)
Get full text
Journal Article
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Motzer, Robert J, Dr, Escudier, Bernard, MD, Tomczak, Piotr, MD, Hutson, Thomas E, DO, Michaelson, M Dror, MD, Negrier, Sylvie, Prof, Oudard, Stephane, Prof, Gore, Martin E, Prof, Tarazi, Jamal, MD, Hariharan, Subramanian, MD, Chen, Connie, PharmD, Rosbrook, Brad, MS, Kim, Sinil, MD, Rini, Brian I, MD
Published in The lancet oncology (01.05.2013)
Published in The lancet oncology (01.05.2013)
Get full text
Journal Article
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Rini, Brian I, Dr, Escudier, Bernard, MD, Tomczak, Piotr, MD, Kaprin, Andrey, Prof, Szczylik, Cezary, MD, Hutson, Thomas E, DO, Michaelson, M Dror, MD, Gorbunova, Vera A, Prof, Gore, Martin E, Prof, Rusakov, Igor G, Prof, Negrier, Sylvie, Prof, Ou, Yen-Chuan, Prof, Castellano, Daniel, MD, Lim, Ho Yeong, Prof, Uemura, Hirotsugu, Prof, Tarazi, Jamal, MD, Cella, David, PhD, Chen, Connie, PharmD, Rosbrook, Brad, MS, Kim, Sinil, MD, Motzer, Robert J, MD
Published in The Lancet (British edition) (03.12.2011)
Published in The Lancet (British edition) (03.12.2011)
Get full text
Journal Article
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Gore, Martin E, Prof, Szczylik, Cezary, Prof, Porta, Camillo, MD, Bracarda, Sergio, Prof, Bjarnason, Georg A, MD, Oudard, Stéphane, Prof, Hariharan, Subramanian, MD, Lee, Se-Hoon, MD, Haanen, John, Prof, Castellano, Daniel, MD, Vrdoljak, Eduard, MD, Schöffski, Patrick, Prof, Mainwaring, Paul, Prof, Nieto, Alejandra, MD, Yuan, Jinyu, PhD, Bukowski, Ronald, Prof
Published in The lancet oncology (01.08.2009)
Published in The lancet oncology (01.08.2009)
Get full text
Journal Article
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
Gore, Martin E, Prof, Griffin, Clare L, MSc, Hancock, Barry, Prof, Patel, Poulam M, Prof, Pyle, Lynda, BSc, Aitchison, Michael, MD, James, Nicholas, Prof, Oliver, Roderick TD, Prof, Mardiak, Jozef, MD, Hussain, Tahera, DPhil, Sylvester, Richard, ScD, Parmar, Mahesh KB, Prof, Royston, Patrick, Prof, Mulders, Peter FA, Prof
Published in The Lancet (British edition) (20.02.2010)
Published in The Lancet (British edition) (20.02.2010)
Get full text
Journal Article